collection
https://read.qxmd.com/read/33778441/elevated-cardiac-troponin-levels-in-geriatric-patients-without-acs-role-of-comorbidities
#1
JOURNAL ARTICLE
Seyed Mahdi Sedighi, Tamas Fulop, Adel Mohammadpour, Michel Nguyen, Patrick Prud'Homme, Abdelouahed Khalil
BACKGROUND: Elevated levels of cardiac troponin T as measured by a high-sensitivity test (hscTnT) are common in geriatric patients with a large spectrum of comorbidities but without acute coronary syndrome (ACS). However, the relative contribution of individual comorbidities has never been clearly addressed. This study aimed to determine the relationship between hscTnT elevation as a response variable and individual comorbidities, and to estimate the impact of individual comorbidities on hscTnT elevation in geriatric patients free of ACS...
March 2021: CJC open
https://read.qxmd.com/read/29892474/ablation-for-atrial-fibrillation-in-heart-failure-with-reduced-ejection-fraction
#2
REVIEW
Jackson J Liang, David J Callans
AF and heart failure with reduced ejection fraction (HFrEF) frequently coexist. Catheter ablation is an increasingly utilised treatment strategy for patients with AF and can be safely performed and is effective in achieving sinus rhythm for patients with HFrEF. Successful ablation may result in improved LV function, clinical heart failure status, quality of life and possibly even mortality. This review summarises the literature analysing efficacy, safety and outcomes of AF ablation for patients with HFrEF.
May 2018: Cardiac Failure Review
https://read.qxmd.com/read/30280640/transcatheter-mitral-valve-repair-in-patients-with-heart-failure
#3
RANDOMIZED CONTROLLED TRIAL
Gregg W Stone, JoAnn Lindenfeld, William T Abraham, Saibal Kar, D Scott Lim, Jacob M Mishell, Brian Whisenant, Paul A Grayburn, Michael Rinaldi, Samir R Kapadia, Vivek Rajagopal, Ian J Sarembock, Andreas Brieke, Steven O Marx, David J Cohen, Neil J Weissman, Michael J Mack
BACKGROUND: Among patients with heart failure who have mitral regurgitation due to left ventricular dysfunction, the prognosis is poor. Transcatheter mitral-valve repair may improve their clinical outcomes. METHODS: At 78 sites in the United States and Canada, we enrolled patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation who remained symptomatic despite the use of maximal doses of guideline-directed medical therapy. Patients were randomly assigned to transcatheter mitral-valve repair plus medical therapy (device group) or medical therapy alone (control group)...
December 13, 2018: New England Journal of Medicine
https://read.qxmd.com/read/31292856/pulmonary-hypertension-in-advanced-heart-failure-assessment-and-management-of-the-failing-rv-and-lv
#4
REVIEW
Sriram D Rao, Jonathan N Menachem, Edo Y Birati, Jeremy A Mazurek
PURPOSE OF REVIEW: In patients with heart failure with reduced ejection fraction, the presence of pulmonary hypertension (PH-LHD) has a significant impact on their prognosis. The purpose of this review is to explain the methods of diagnosing PH-LHD and then discuss the available therapeutic options. RECENT FINDINGS: We begin by examining the methods of assessment of PH-LHD-echocardiography, cardiopulmonary exercise testing, and right heart catheterization-with a particular focus on the importance of accurate measurement to ensure the proper determination of PH-LHD...
October 2019: Current Heart Failure Reports
https://read.qxmd.com/read/31043318/micrornas-as-potential-biomarkers-in-congenital-heart-surgery
#5
JOURNAL ARTICLE
Serban C Stoica, Dan M Dorobantu, Antonella Vardeu, Giovanni Biglino, Kerrie L Ford, Domenico V Bruno, Mustafa Zakkar, Andrew Mumford, Gianni D Angelini, Massimo Caputo, Costanza Emanueli
OBJECTIVE: Pediatric congenital heart surgery (CHS) involves intracardiac, valvular, and vascular repairs. Accurate tools to aid short-term outcome prediction in pediatric CHS are lacking. Clinical scores, such as the vasoactive-inotrope score and ventilation index, are used to define outcome in clinical studies. MicroRNA-1-3p (miR-1) is expressed by both cardiomyocytes and vascular cells and is regulated by hypoxia. In adult patients, miR-1 increases in the circulation after open-heart cardiac surgery, suggesting its potential as a clinical biomarker...
April 2020: Journal of Thoracic and Cardiovascular Surgery
https://read.qxmd.com/read/31097157/10-year-risk-equations-for-incident-heart-failure-in-the-general-population
#6
JOURNAL ARTICLE
Sadiya S Khan, Hongyan Ning, Sanjiv J Shah, Clyde W Yancy, Mercedes Carnethon, Jarett D Berry, Robert J Mentz, Emily O'Brien, Adolfo Correa, Navin Suthahar, Rudolf A de Boer, John T Wilkins, Donald M Lloyd-Jones
BACKGROUND: Primary prevention strategies to mitigate the burden of heart failure (HF) are urgently needed. However, no validated risk prediction tools are currently in use. OBJECTIVES: This study sought to derive 10-year risk equations of developing incident HF. METHODS: Race- and sex-specific 10-year risk equations for HF were derived and validated from individual-level data from 7 community-based cohorts with at least 12 years of follow-up...
May 21, 2019: Journal of the American College of Cardiology
https://read.qxmd.com/read/31236393/application-of-pulse-index-continuous-cardiac-output-system-in-elderly-patients-with-acute-myocardial-infarction-complicated-by-cardiogenic-shock-a-prospective-randomized-study
#7
JOURNAL ARTICLE
Yuan-Bo Zhang, Zhi-Zhong Zhang, Jun-Xia Li, Yu-Hong Wang, Wei-Lin Zhang, Xin-Li Tian, Yun-Feng Han, Meng Yang, Yu Liu
BACKGROUND: Cardiogenic shock (CS) secondary to acute myocardial infarction (AMI) complicates management of the condition, and often leads to poor prognosis. Prompt and accurate monitoring of cardiovascular and accompanying hemodynamic changes is crucial in achieving adequate management of the condition. Advances in technology has availed procedures such as pulse index continuous cardiac output (PiCCO), which can offer precise monitoring of cardiovascular functions and hemodynamic parameters...
June 6, 2019: World Journal of Clinical Cases
https://read.qxmd.com/read/31111162/copd-and-heart-failure-differential-diagnosis-and-comorbidity
#8
REVIEW
G Güder, S Störk
Heart failure (HF) and chronic obstructive pulmonary disease (COPD) represent the most important differential diagnoses of dyspnea in elderly people. Heart failure is the inability of the heart to pump sufficient amounts of blood through the cardiovascular system. Pump failure is caused by compromised contractility and/or filling of the ventricles leading to forward and backward failure and subsequently to dyspnea. In COPD, the destruction and remodeling processes of the bronchiolar architecture inhibit proper exhalation of air, thereby leading to exhaustion of the thoracic muscles, insufficient oxygen diffusion, and dyspnea...
September 2019: Herz
https://read.qxmd.com/read/31148603/heart-failure-with-preserved-ejection-fraction-in-elderly-from-pathophysiology-to-treatment-an-unresolved-problem
#9
REVIEW
Matteo Beltrami, Carlo Fumagalli
Heart failure with preserved ejection fraction (HFpEF) has a significant impact on healthcare resources and while its occurrence in the elderly is increasing, its prognosis has not improved. Despite the prevalence of HFpEF, the understanding of its pathophysiology is still incomplete, and optimal treatment remains largely undefined. The net clinical benefit of medical treatment with ACE inhibitors, ARBs, MRAs and beta-blockers has led to the incorporation of these drugs into HF clinical practice guidelines...
May 31, 2019: Monaldi Archives for Chest Disease
https://read.qxmd.com/read/31217795/cardiovascular-risk-prediction-in-the-elderly
#10
REVIEW
Kartik Kumar, Luis Afonso
Heart failure (HF) in the elderly, besides being a leading cause of mortality and morbidity, is rapidly increasing in prevalence with patients aged 65 and older accounting for more than 75% of heart failure hospitalizations. Elderly patients have historically been unrepresented in clinical HF trials and often present with multiple comorbidities, including frailty, depression, nutritional, functional and cognitive impairments. Additionally, pharmacologic challenges such as adherence to therapy, polypharmacy, altered drug pharmacokinetics and/or renal derangements make them less likely to receive guideline-directed medical therapies for HF...
May 2019: Journal of Geriatric Cardiology: JGC
https://read.qxmd.com/read/31217796/heart-failure-with-preserved-ejection-fraction-in-the-elderly-pathophysiology-diagnostic-and-therapeutic-approach
#11
REVIEW
Ernesto Ruiz Duque, Alexandros Briasoulis, Paulino A Alvarez
Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome characterized by symptoms and sings of heart failure with elevated left ventricular filling pressures at rest or during exercise. It is the most common type of heart failure in the elderly and its prevalence increases with age and is higher in females at any given age. HFpEF is frequently accompanied of comorbid conditions such as diabetes mellitus, obesity, atrial fibrillation and renal dysfunction. The diagnosis relies in the integration of clinical information, laboratory data and interpretation of cardiac imaging and hemodynamic findings at rest and during exercise...
May 2019: Journal of Geriatric Cardiology: JGC
https://read.qxmd.com/read/31252445/-the-cardiorenal-syndrome
#12
JOURNAL ARTICLE
Florian Gunnar Scurt, Tim Kuczera, Peter René Mertens, Christos Chatzikyrkou
Chronic heart failure is associated with high morbidity and mortality and is the most common hospital diagnosis for elderly patients. Concomitant or superimposed acute or chronic kidney injury, as is the case with cardiorenal syndrome, has a dramatic impact on the outcome. The inhibition of the neurohumoral axis and the adequate treatment of hypervolemia are fundamental elements of modern cardiac insufficiency therapies. In addition to optimal conservative therapy, there are other options: VAD implantation, hemodialysis and peritoneal dialysis...
July 2019: Deutsche Medizinische Wochenschrift
https://read.qxmd.com/read/30398532/reduced-salt-intake-for-heart-failure-a-systematic-review
#13
JOURNAL ARTICLE
Kamal R Mahtani, Carl Heneghan, Igho Onakpoya, Stephanie Tierney, Jeffrey K Aronson, Nia Roberts, F D Richard Hobbs, David Nunan
IMPORTANCE: Recent estimates suggest that more than 26 million people worldwide have heart failure. The syndrome is associated with major symptoms, significantly increased mortality, and extensive use of health care. Evidence-based treatments influence all these outcomes in a proportion of patients with heart failure. Current management also often includes advice to reduce dietary salt intake, although the benefits are uncertain. OBJECTIVE: To systematically review randomized clinical trials of reduced dietary salt in adult inpatients or outpatients with heart failure...
December 1, 2018: JAMA Internal Medicine
https://read.qxmd.com/read/31233411/myocardial-viability-heart-failure-perspective
#14
REVIEW
Ashley Bock, Jerry D Estep
PURPOSE OF REVIEW: This review highlights the different imaging modalities available to assess myocardial viability in patients with heart failure and coronary artery disease (CAD) being considered for revascularization. RECENT FINDINGS: Myocardial viability can be determined by a variety of cardiac imaging modalities. Recent studies have confirmed the use of cardiovascular magnetic resonance imaging (CMR) in patients with heart failure and CAD, suggesting that those who undergo revascularization but have evidence of residual viable or 'jeopardized' myocardium have increased mortality compared with those who achieve complete revascularization...
September 2019: Current Opinion in Cardiology
https://read.qxmd.com/read/31248701/2019-acc-aha-ase-key-data-elements-and-definitions-for-transthoracic-echocardiography-a-report-of-the-american-college-of-cardiology-american-heart-association-task-force-on-clinical-data-standards-writing-committee-to-develop-cardiovascular-endpoints-data
#15
JOURNAL ARTICLE
Pamela S Douglas, Blase A Carabello, Roberto M Lang, Leo Lopez, Patricia A Pellikka, Michael H Picard, James D Thomas, Paul Varghese, Tracy Y Wang, Neil J Weissman, Rebecca Wilgus
No abstract text is available yet for this article.
July 23, 2019: Journal of the American College of Cardiology
https://read.qxmd.com/read/31120823/management-of-myocarditis-related-cardiomyopathy-in-adults
#16
REVIEW
Carsten Tschöpe, Leslie T Cooper, Guillermo Torre-Amione, Sophie Van Linthout
Myocarditis is generally a mild and self-limited consequence of systemic infection of cardiotropic viruses. However, patients can develop a temporary or permanent impairment of cardiac function including acute cardiomyopathy with hemodynamic compromise or severe arrhythmias. In this setting, specific causes of inflammation are associated with variable risks of death and transplantation. Recent translational studies suggest that treatments tailored to specific causes of myocarditis may impact clinical outcomes when added to guideline-directed medical care...
May 24, 2019: Circulation Research
https://read.qxmd.com/read/31222929/heart-failure-association-of-the-european-society-of-cardiology-practical-guidance-on-the-use-of-natriuretic-peptide-concentrations
#17
REVIEW
Christian Mueller, Kenneth McDonald, Rudolf A de Boer, Alan Maisel, John G F Cleland, Nikola Kozhuharov, Andrew J S Coats, Marco Metra, Alexandre Mebazaa, Frank Ruschitzka, Mitja Lainscak, Gerasimos Filippatos, Petar M Seferovic, Wouter C Meijers, Antoni Bayes-Genis, Thomas Mueller, Mark Richards, James L Januzzi
Natriuretic peptide [NP; B-type NP (BNP), N-terminal proBNP (NT-proBNP), and midregional proANP (MR-proANP)] concentrations are quantitative plasma biomarkers for the presence and severity of haemodynamic cardiac stress and heart failure (HF). End-diastolic wall stress, intracardiac filling pressures, and intracardiac volumes seem to be the dominant triggers. This paper details the most important indications for NPs and highlights 11 key principles underlying their clinical use shown below. NPs should always be used in conjunction with all other clinical information...
June 2019: European Journal of Heart Failure
https://read.qxmd.com/read/31203254/oral-anticoagulants-in-atrial-fibrillation-with-valvular-heart-disease-and-bioprosthetic-heart-valves
#18
JOURNAL ARTICLE
Aaqib H Malik, Srikanth Yandrapalli, Wilbert S Aronow, Julio A Panza, Howard A Cooper
OBJECTIVE: Current guidelines endorse the use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation (AF). However, little is known about their safety and efficacy in valvular heart disease (VHD). Similarly, there is a paucity of data regarding NOACs use in patients with a bioprosthetic heart valve (BPHV). We, therefore, performed a network meta-analysis in the subgroups of VHD and meta-analysis in patients with a BPHV. METHODS: PubMed, Cochrane and Embase were searched for randomised controlled trials...
September 2019: Heart
https://read.qxmd.com/read/30747965/association-of-left-ventricular-ejection-fraction-and-symptoms-with-mortality-after-elective-noncardiac-surgery-among-patients-with-heart-failure
#19
JOURNAL ARTICLE
Benjamin J Lerman, Rita A Popat, Themistocles L Assimes, Paul A Heidenreich, Sherry M Wren
Importance: Heart failure is an established risk factor for postoperative mortality, but how left ventricular ejection fraction and heart failure symptoms affect surgical outcomes is not fully described. Objectives: To determine the risk of postoperative mortality among patients with heart failure at various levels of echocardiographic (left ventricular systolic dysfunction) and clinical (symptoms) severity compared with those without heart failure and to evaluate how risk varies across levels of surgical complexity...
February 12, 2019: JAMA
https://read.qxmd.com/read/30571262/2018-american-heart-association-focused-update-on-advanced-cardiovascular-life-support-use-of-antiarrhythmic-drugs-during-and-immediately-after-cardiac-arrest-an-update-to-the-american-heart-association-guidelines-for-cardiopulmonary-resuscitation-and-emergency
#20
JOURNAL ARTICLE
Ashish R Panchal, Katherine M Berg, Peter J Kudenchuk, Marina Del Rios, Karen G Hirsch, Mark S Link, Michael C Kurz, Paul S Chan, José G Cabañas, Peter T Morley, Mary Fran Hazinski, Michael W Donnino
Antiarrhythmic medications are commonly administered during and immediately after a ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. However, it is unclear whether these medications improve patient outcomes. This 2018 American Heart Association focused update on advanced cardiovascular life support guidelines summarizes the most recent published evidence for and recommendations on the use of antiarrhythmic drugs during and immediately after shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest...
December 4, 2018: Circulation
label_collection
label_collection
5738
1
2
2019-03-04 21:30:09
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.